KR20200121286A - 방사선-민감성 조직에서 세포보호제의 선택적 증가 및 이의 용도 - Google Patents

방사선-민감성 조직에서 세포보호제의 선택적 증가 및 이의 용도 Download PDF

Info

Publication number
KR20200121286A
KR20200121286A KR1020207017925A KR20207017925A KR20200121286A KR 20200121286 A KR20200121286 A KR 20200121286A KR 1020207017925 A KR1020207017925 A KR 1020207017925A KR 20207017925 A KR20207017925 A KR 20207017925A KR 20200121286 A KR20200121286 A KR 20200121286A
Authority
KR
South Korea
Prior art keywords
radiation
tissue
dose
organ
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207017925A
Other languages
English (en)
Korean (ko)
Inventor
제임스 투어
컬렌 타니구치
캐시 메이슨
Original Assignee
윌리엄 마쉬 라이스 유니버시티
보드 오브 레젼츠, 더 유니버시티 오브 텍사스 시스템
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리엄 마쉬 라이스 유니버시티, 보드 오브 레젼츠, 더 유니버시티 오브 텍사스 시스템, 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 윌리엄 마쉬 라이스 유니버시티
Publication of KR20200121286A publication Critical patent/KR20200121286A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207017925A 2017-11-21 2018-11-19 방사선-민감성 조직에서 세포보호제의 선택적 증가 및 이의 용도 Ceased KR20200121286A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589155P 2017-11-21 2017-11-21
US62/589,155 2017-11-21
PCT/US2018/061888 WO2019103983A1 (en) 2017-11-21 2018-11-19 Selective accretion of cytoprotectant in radiation-sensitive tissues and uses thereof

Publications (1)

Publication Number Publication Date
KR20200121286A true KR20200121286A (ko) 2020-10-23

Family

ID=66631627

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207017925A Ceased KR20200121286A (ko) 2017-11-21 2018-11-19 방사선-민감성 조직에서 세포보호제의 선택적 증가 및 이의 용도

Country Status (8)

Country Link
US (1) US11478489B2 (https=)
EP (1) EP3713534A4 (https=)
JP (2) JP2021510380A (https=)
KR (1) KR20200121286A (https=)
CN (1) CN111867599A (https=)
AU (2) AU2018372917A1 (https=)
CA (1) CA3083238C (https=)
WO (1) WO2019103983A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855445B2 (en) 2016-04-01 2018-01-02 Varian Medical Systems, Inc. Radiation therapy systems and methods for delivering doses to a target volume
US10092774B1 (en) 2017-07-21 2018-10-09 Varian Medical Systems International, AG Dose aspects of radiation therapy planning and treatment
US11712579B2 (en) 2017-07-21 2023-08-01 Varian Medical Systems, Inc. Range compensators for radiation therapy
US11590364B2 (en) 2017-07-21 2023-02-28 Varian Medical Systems International Ag Material inserts for radiation therapy
US10549117B2 (en) 2017-07-21 2020-02-04 Varian Medical Systems, Inc Geometric aspects of radiation therapy planning and treatment
US10843011B2 (en) 2017-07-21 2020-11-24 Varian Medical Systems, Inc. Particle beam gun control systems and methods
US10183179B1 (en) 2017-07-21 2019-01-22 Varian Medical Systems, Inc. Triggered treatment systems and methods
EP3654976A1 (en) 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
US11007381B2 (en) 2017-11-16 2021-05-18 Varian Medical Systems, Inc Increased beam output and dynamic field shaping for radiotherapy system
US10910188B2 (en) 2018-07-25 2021-02-02 Varian Medical Systems, Inc. Radiation anode target systems and methods
US10814144B2 (en) 2019-03-06 2020-10-27 Varian Medical Systems, Inc. Radiation treatment based on dose rate
US11116995B2 (en) 2019-03-06 2021-09-14 Varian Medical Systems, Inc. Radiation treatment planning based on dose rate
US11103727B2 (en) 2019-03-08 2021-08-31 Varian Medical Systems International Ag Model based PBS optimization for flash therapy treatment planning and oncology information system
US11090508B2 (en) 2019-03-08 2021-08-17 Varian Medical Systems Particle Therapy Gmbh & Co. Kg System and method for biological treatment planning and decision support
US10918886B2 (en) 2019-06-10 2021-02-16 Varian Medical Systems, Inc. Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping
US11291859B2 (en) 2019-10-03 2022-04-05 Varian Medical Systems, Inc. Radiation treatment planning for delivering high dose rates to spots in a target
US12390662B2 (en) 2020-04-02 2025-08-19 Siemens Healthineers International Ag System and method for proton therapy treatment planning with proton energy and spot optimization
US11865361B2 (en) 2020-04-03 2024-01-09 Varian Medical Systems, Inc. System and method for scanning pattern optimization for flash therapy treatment planning
US11541252B2 (en) 2020-06-23 2023-01-03 Varian Medical Systems, Inc. Defining dose rate for pencil beam scanning
US11957934B2 (en) 2020-07-01 2024-04-16 Siemens Healthineers International Ag Methods and systems using modeling of crystalline materials for spot placement for radiation therapy
US12064645B2 (en) 2020-07-02 2024-08-20 Siemens Healthineers International Ag Methods and systems used for planning radiation treatment
CN113768940A (zh) * 2021-08-25 2021-12-10 中国辐射防护研究院 一种放射性肺损伤的防护方法
WO2025075691A1 (en) * 2023-10-07 2025-04-10 Xerient Pharma Ltd. Irradiation protection methods uses and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
WO2007047315A1 (en) 2005-10-20 2007-04-26 Albemarle Corporation Amifostine dihydrate crystalline composition
US9393439B2 (en) 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US9408882B2 (en) 2011-03-18 2016-08-09 Albert Einstein College Of Medicine, Inc. Oral administration of melanin for protection against radiation
CN102210694A (zh) * 2011-04-12 2011-10-12 上海长征医院 一种氨磷汀口服制剂及其制备方法

Also Published As

Publication number Publication date
JP2021510380A (ja) 2021-04-22
AU2024227095A1 (en) 2024-10-24
WO2019103983A1 (en) 2019-05-31
CA3083238A1 (en) 2019-05-31
EP3713534A1 (en) 2020-09-30
EP3713534A4 (en) 2021-08-25
AU2018372917A1 (en) 2020-06-18
JP2024026262A (ja) 2024-02-28
US11478489B2 (en) 2022-10-25
US20200360406A1 (en) 2020-11-19
CN111867599A (zh) 2020-10-30
CA3083238C (en) 2024-02-13

Similar Documents

Publication Publication Date Title
KR20200121286A (ko) 방사선-민감성 조직에서 세포보호제의 선택적 증가 및 이의 용도
US12109256B2 (en) Radiohalogenated agents for in situ immune modulated cancer vaccination
ES2811367T3 (es) Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer
US10238630B2 (en) Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
US10111871B2 (en) Nanoparticle drug delivery system and method of treating cancer and neurotrauma
ES3015717T3 (en) A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis
Karthika et al. Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance?
CN102056609B (zh) 药物组合
JP2022519777A (ja) 処置誘導性の胃腸傷害を防止又は処置する方法
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
US12409158B2 (en) Combination therapy for treating cancer
ES2842431T3 (es) Composición para prevenir o tratar mucositis que comprende NecroX como ingrediente eficaz
US20130164379A1 (en) Nanoparticle micelle coated compositions
ES2949940T3 (es) Compuestos para uso en la prevención y/o el tratamiento de esteatosis hepática no alcohólica y esteatohepatitis no alcohólica
JP2002540172A (ja) 腫瘍治療の増強のためのスフィンゴミエリン含有調製物
US9872831B2 (en) Pharmaceutical composition of oxidised avidin suitable for inhalation
US20220118116A1 (en) Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
TWI620566B (zh) 三萜混合物用以治療多發性硬化的用途
CN116212026A (zh) 巨噬细胞封闭剂在制备adc药物副反应治疗或预防产品中的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200619

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211015

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231001

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240404

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231001

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I